vimarsana.com
  1. Home
  2. Live Updates
  3. Kevin Garey - Breaking News

Latest Breaking News On - Kevin garey - Page 1 : vimarsana.com

Acurx Pharmaceuticals, Inc Reports First Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals, Inc Reports First Quarter 2024 Results and Provides Business Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesRobertg shawahDavidp luciKevin gareyAcurx pharmaceuticalsInternational cdifficile symposiumEuropean medicines agencyPrnewswire acurx pharmaceuticals incAcurx pharmaceuticals incAnaerobe society of americaDrug administrationInfectious diseases society of americaUniversity of houston college pharmacyEuropean society of microbiologyExchange commission on formMarketing authorization

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.

United statesComunidad autonoma de catalunaKevin gareyEugenie basseresDavidp luciCompany phSociety or healthcare epidemiology of americaGlobal european society of clinical microbiologyTrial oversight committeeData monitoring committeeExchange commission on formInfectious diseases society of americaEuropean society of clinical microbiologyResearch scientistAcurx pharmaceuticalsAcurx pharmaceuticals inc

Reduced Vancomycin Susceptibility Tied to Poorer C difficile Outcomes

Poorer outcomes seen for 30-day sustained clinical response and 14-day initial cure rates.

Kevin gareyTaryna eubankUniversity of houstonUniversity of houston college pharmacyHealthday newsClinical infectiousHouston college

Vancomycin May Be Losing Strength Against Common Deadly Infection

Key Takeaways

University of houstonUnited statesKevin gareyAnne gonzales lunaUs centers for diseaseUniversity of houston college pharmacyHealthday newsHouston collegeDisease controlClinical infectiousInfectious diseaseConsumer news

Antibiotic for Treating Deadly Superbug C difficile May No Longer Be Effective

Vancomycin, the first line of treatment for <i>C. difficile</i> infection, is becoming less effective.

Annej gonzales lunaKevin gareyUniversity of houston collegeTechnology networkDepartment of pharmacy practiceTranslational researchUh college of pharmacyHouston collegePharmacy practiceClinical infectious

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.